Subject(s)
Immunocompromised Host , Immunosuppressive Agents/adverse effects , Inflammatory Bowel Diseases/immunology , Opportunistic Infections/immunology , Humans , Immunosuppressive Agents/therapeutic use , Inflammatory Bowel Diseases/complications , Inflammatory Bowel Diseases/drug therapy , Opportunistic Infections/complications , Opportunistic Infections/diagnosis , Opportunistic Infections/therapy , VaccinationABSTRACT
Our knowledge of COVID-19 is changing and evolving rapidly, with novel insights and recommendations, almost on a daily basis. It behooves the medical community to provide updated information on a regular basis, on best practice to facilitate optimal care of infected patients and on appropriate advice for the general population. This is particularly important in the case of patients with chronic conditions, such as inflammatory bowel disease [IBD]. In this review, we have compiled existing evidence on the impact of COVID-19 in IBD patients and provide guidance on the most appropriate care to adopt during the pandemic. Our review highlights that IBD, per se, is not a risk factor for COVID-19. However, all IBD patients with symptoms should be tested for SARS-CoV-2 and the procedures for disease management should be carefully adapted: [i] in SARS-CoV-2-positive IBD patients, medical treatments should be re-evaluated [with a particular focus on corticosteroids] always with the purpose of treating active disease and maintaining remission; [ii] non-urgent surgeries and endoscopic procedures should be postponed for all patients; [iii] online consultancy should be implemented; and [iv] hospitalization and surgery should be limited to life-threatening situations.
Subject(s)
Betacoronavirus , Coronavirus Infections/prevention & control , Inflammatory Bowel Diseases/therapy , Pandemics/prevention & control , Pneumonia, Viral/prevention & control , Betacoronavirus/isolation & purification , COVID-19 , COVID-19 Testing , Clinical Laboratory Techniques , Coronavirus Infections/complications , Coronavirus Infections/diagnosis , Global Health , Health Care Rationing/methods , Health Care Rationing/standards , Humans , Infection Control/methods , Infection Control/standards , Inflammatory Bowel Diseases/complications , Pneumonia, Viral/complications , Pneumonia, Viral/diagnosis , Risk Assessment , Risk Factors , SARS-CoV-2Subject(s)
Biological Therapy/methods , Psoriasis/drug therapy , Adolescent , Adult , Algorithms , Biological Therapy/adverse effects , Child , Child, Preschool , Clinical Decision-Making , Contraindications, Drug , Drug Substitution , Humans , Medication Adherence , Neoplasms/chemically induced , Neoplasms/prevention & control , Preconception Care/methods , Prenatal Care/methods , Risk Factors , Social Support , Treatment Outcome , Tuberculosis/complications , Tuberculosis/diagnosis , Vaccination/adverse effects , Virus Diseases/complicationsABSTRACT
Patients with vulval aphthae, also termed Lipschütz ulcers, often present to genitourinary medicine clinics. Typically, these ulcers present as acute, painful, vulval ulcers in young women and adolescents. The aetiology is unknown, and often these ulcers are accompanied by flu-like symptoms. Previous case reports have linked such lesions to acute viral infections such as Epstein-Barr virus, cytomegalovirus and influenza A. We report the first case of influenza B virus and adenovirus infections associated with this presentation.
Subject(s)
Influenza B virus/isolation & purification , Influenza, Human/complications , Ulcer/diagnosis , Vulvar Diseases/diagnosis , Acyclovir/therapeutic use , Adolescent , Antiviral Agents/therapeutic use , Female , Humans , Influenza, Human/diagnosis , Influenza, Human/drug therapy , Polymerase Chain Reaction , Skin Ulcer/etiology , Skin Ulcer/pathology , Treatment Outcome , Ulcer/virology , Vulvar Diseases/drug therapy , Vulvar Diseases/virologySubject(s)
Inflammatory Bowel Diseases/complications , Opportunistic Infections/etiology , Adolescent , Adult , Age Factors , HIV Infections/diagnosis , HIV Infections/etiology , HIV Infections/prevention & control , HIV Infections/therapy , Hepatitis B/diagnosis , Hepatitis B/etiology , Hepatitis B/prevention & control , Hepatitis B/therapy , Hepatitis C/diagnosis , Hepatitis C/etiology , Hepatitis C/prevention & control , Hepatitis C/therapy , Herpesviridae Infections/diagnosis , Herpesviridae Infections/etiology , Herpesviridae Infections/prevention & control , Herpesviridae Infections/therapy , Humans , Immunocompromised Host , Influenza, Human/diagnosis , Influenza, Human/etiology , Influenza, Human/prevention & control , Influenza, Human/therapy , Middle Aged , Mycoses/diagnosis , Mycoses/etiology , Mycoses/prevention & control , Mycoses/therapy , Opportunistic Infections/diagnosis , Opportunistic Infections/prevention & control , Opportunistic Infections/therapy , Papillomavirus Infections/diagnosis , Papillomavirus Infections/etiology , Papillomavirus Infections/prevention & control , Papillomavirus Infections/therapy , Parasitic Diseases/diagnosis , Parasitic Diseases/etiology , Parasitic Diseases/prevention & control , Parasitic Diseases/therapy , Risk Factors , Young AdultABSTRACT
The estimated frequency of parainfluenza virus 3 (PIV-3) infections following haematopoietic SCT (HSCT) is 2-7%, whereas reported mortality ranges from 18 to 33%. We report a retrospective outcome analysis following an outbreak of PIV-3 infection in our transplant unit. A total of 16 HSCT patients developed PIV-3 infection. All patients had upper respiratory tract infection, whereas lower respiratory tract infection occurred in 8 patients. Overall, 13 patients were treated with aerosolised Ribavirin (2 g t.d.s. for 5 days) and i.v. Ig (0.5 g/kg) as per standard protocol. One patient refused treatment, whereas two patients with full immune reconstitution were not treated. Overall mortality was 62.5%. Sepsis with multi-organ failure and the presence of pulmonary co-pathogens were both significantly associated with PIV-3-related mortality. Our series confirms that high mortality is associated with PIV-3 infection in HSCT recipients. In patients who develop PIV-3 infection, despite strict enforcement of infection control policies, the best strategy might be careful risk assessment, with effective broad-spectrum anti-microbials in those who are at risk of secondary infection.
Subject(s)
Disease Outbreaks , Hematologic Neoplasms/therapy , Hematopoietic Stem Cell Transplantation , Multiple Organ Failure/mortality , Parainfluenza Virus 3, Human , Respirovirus Infections/mortality , Sepsis/mortality , Adult , Aged , Anti-Bacterial Agents/administration & dosage , Antiviral Agents/administration & dosage , Female , Hematologic Neoplasms/mortality , Humans , Infection Control/methods , Infections/drug therapy , Infections/etiology , Infections/mortality , Lung Diseases/drug therapy , Lung Diseases/etiology , Lung Diseases/mortality , Male , Middle Aged , Multiple Organ Failure/drug therapy , Multiple Organ Failure/etiology , Respirovirus Infections/drug therapy , Respirovirus Infections/etiology , Ribavirin/administration & dosage , Sepsis/drug therapy , Sepsis/etiology , Survival Rate , Transplantation, Autologous , Transplantation, HomologousABSTRACT
AIMS: To identify the extent of nosocomial adenovirus keratoconjunctivitis (AKC) and assess the effect of a new infection-control policy. METHODS: Nosocomial AKC was defined as AKC in patients attending the hospital within 3 weeks of a previous visit for an unrelated non-infective condition. An audit of culture-proven nosocomial AKC was carried out from October 1998 to September 1999 to establish its extent in our outpatient department. A new infection-control policy for AKC was introduced in June 2001 that differed from the previous policy by segregating suspected AKC cases in a separate waiting area and examination room, and by expediting their examination, to reduce their exposure to both staff and patients in the common waiting areas. In October 2002, AKC was made an index infection and subjected to continual quarterly audit; the figures for this until December 2005 are reported. RESULTS: In the 1998-9 audit, before the introduction of the new infection-control measures, 48.4% (75/155) AKC infections were nosocomial. In the 12 months following the introduction of the quarterly audit in October 2002, 22.7% (5/22) were nosocomial, but thereafter the numbers of nosocomial cases dropped to 3.4% (8/235). CONCLUSION: Introduction of audit of nosocomial AKC infection identified that there was chronic cross-infection in the Moorfields Eye Hospital Accident and Emergency Department. This was controlled by the introduction of patient segregation, as an additional infection-control measure, which has almost eliminated nosocomial AKC transmission in the hospital.
Subject(s)
Adenovirus Infections, Human , Cross Infection , Eye Infections, Viral , Infection Control/methods , Keratoconjunctivitis , Adenovirus Infections, Human/diagnosis , Adenovirus Infections, Human/prevention & control , Adenovirus Infections, Human/virology , Clinical Audit , Cross Infection/diagnosis , Cross Infection/prevention & control , Cross Infection/virology , Eye Infections, Viral/diagnosis , Eye Infections, Viral/prevention & control , Eye Infections, Viral/virology , Female , Humans , Keratoconjunctivitis/diagnosis , Keratoconjunctivitis/prevention & control , Keratoconjunctivitis/virology , Male , Patient IsolationABSTRACT
Two organ recipients developed serologic evidence of syphilis infection after renal transplantation from a common deceased donor with a history of treated syphilis. Testing of donor serum for syphilis, which occurred after transplantation, gave results interpreted as consistent with past infection. However, subsequent serologic results in the recipients suggested transmission of infection at transplantation due to active infection of the donor. This may be explained by recent donor re-infection in view of the current syphilis epidemic in the United Kingdom. An initial error in the treatment of recipients further served to highlight unfamiliarity in managing this resurgent infection in the context of organ transplantation.
Subject(s)
Kidney Transplantation/adverse effects , Syphilis/transmission , Adult , Antibodies, Bacterial/analysis , Female , Follow-Up Studies , Humans , Male , Syphilis/microbiology , Treponema pallidum/immunologyABSTRACT
Two children, boys of 8 and 13 years, presented with measles-associated encephalopathy several years after kidney transplantation for congenital nephrotic syndrome. In the absence of prior clinical measles, the neurological symptoms initially eluded diagnosis, but retrospective analysis of stored samples facilitated the diagnosis of measles-associated encephalopathy without recourse to biopsy of deep cerebral lesions. Each had received a single dose of measles mumps and rubella vaccine before 12 months of age. Prior vaccination, reduction of immunosuppression and treatment with intravenous immunoglobulin and ribavirin may have contributed to their survival. Persistent measles virus RNA shedding, present in one child, was not controlled by treatment with i.v. ribavirin. Two years later, both patients continue to have functioning allografts with only minimal immunosuppression. These cases illustrate the difficulty in diagnosing measles-associated encephalopathy in the immunocompromised host, even in the era of molecular diagnostics, and highlight the renewed threat of neurological disease in communities with incomplete herd immunity.
Subject(s)
Kidney Transplantation/physiology , Measles/complications , Subacute Sclerosing Panencephalitis/epidemiology , Adolescent , Biopsy , Brain/pathology , Child , Humans , Infant , Measles-Mumps-Rubella Vaccine , Treatment OutcomeABSTRACT
Cytomegalovirus (CMV) is usually a complication of renal/solid organ or bone marrow transplantation. We describe three cases of severe CMV in the context of vasculitis immunosuppression.
Subject(s)
Bone Marrow Transplantation/adverse effects , Cytomegalovirus Infections/etiology , Cytomegalovirus/isolation & purification , Kidney Transplantation/adverse effects , Vasculitis/drug therapy , Acute Disease , Adult , Aged , Aged, 80 and over , Humans , Immunosuppressive Agents/adverse effects , Immunosuppressive Agents/therapeutic use , Male , Middle AgedABSTRACT
We present a new system that integrates computer graphics, physics-based modeling, and interactive visualization to assist knee study and surgical operation. First, we discuss generating patient-specific three-dimensional (3-D) knee models from patient's magnetic resonant images (MRIs). The 3-D model is obtained by deforming a reference model to match the MRI dataset. Second, we present simulating knee motion that visualizes patient-specific motion data on the patient-specific knee model. Third, we introduce visualizing biomechanical information on a patient-specific model. The focus is on visualizing contact area, contact forces, and menisci deformation. Traditional methods have difficulty in visualizing knee contact area without using invasive methods. The approach presented here provides an alternative of visualizing the knee contact area and forces without any risk to the patient. Finally, a virtual surgery can be performed. The constructed 3-D knee model is the basis of motion simulation, biomechanical visualization, and virtual surgery. Knee motion simulation determines the knee rotation angles as well as knee contact points. These parameters are used to solve the biomechanical model. Our results integrate 3-D construction, motion simulation, and biomechanical visualization into one system. Overall, the methodologies here are useful elements for future virtual medical systems where all the components of visualization, automated model generation, and surgery simulation come together.
Subject(s)
Knee/physiology , Knee/surgery , Therapy, Computer-Assisted/instrumentation , User-Computer Interface , Biomechanical Phenomena , Computer Graphics , Computer Simulation , Humans , Imaging, Three-Dimensional , Magnetic Resonance ImagingSubject(s)
Antiviral Agents/therapeutic use , Burkitt Lymphoma/drug therapy , Foscarnet/therapeutic use , HIV Infections/complications , Herpesvirus 4, Human , Anti-HIV Agents/therapeutic use , Burkitt Lymphoma/etiology , HIV Infections/drug therapy , HIV Infections/immunology , Humans , Immunocompromised Host/immunologyABSTRACT
Hepatitis C virus (HCV) seroconversion was detected by routine screening in a haemodialysis patient, Patient 1. Serological investigations were undertaken over the following 3 months to determine if further transmission to other patients on the unit had occurred. No additional cases were identified. Twenty-two haemodialysis patients known to have HCV infection were investigated using molecular epidemiological methods to determine if transmission between patients had occurred. HCV viraemia was demonstrated by polymerase chain reaction in 19 of 22 patients (86%). Genotyping showed that eight patients were infected with genotype 1, three with genotype 3 and eight, including Patient 1, with genotype 2. Phylogenetic analysis of viral sequences from the eight patients with genotype 2 revealed three, including Patient 1,with a novel subtype of HCV type 2, and revealed close similarity between viral sequences from patient 1 and those from one other patient, suggesting transmission. This was consistent with haemodialysis histories. Among other patients with genotype 2, there were two with subtype 2a and three others with three separate novel subtypes, as yet undesignated. With the exception of patient 1, all patients infected with novel subtypes were of Afro-Caribbean origin. The HCV prevalence among patients on the haemodialysis unit was high (14%), which may reflect the ethnicity of our haemodialysis population. This case emphasises the risk of nosocomial transmission and the importance of infection control procedures on haemodialysis units, and highlights the usefulness of molecular epidemiological techniques for the investigation of outbreaks of HCV infection.
Subject(s)
Cross Infection , Hepacivirus/genetics , Hepatitis C/transmission , Adult , Aged , Base Sequence , Cross Infection/transmission , Cross Infection/virology , Disease Outbreaks , Genotype , Hemodialysis Units, Hospital , Hepacivirus/immunology , Hepacivirus/isolation & purification , Hepatitis C/blood , Hepatitis C/epidemiology , Hepatitis C/virology , Hepatitis C Antibodies/blood , Humans , Male , Molecular Sequence Data , Prevalence , RNA, Viral/bloodABSTRACT
Monoclonal antibodies reactive with the HNK-1 epitope of myelin-associated glycoprotein (MAG) and the sulphate-3-glucuronyl paragloboside (SGPG)-like glycolipids are often found in the serum of patients with IgM paraprotein-associated demyelinating neuropathy. The presence of such antibodies in patients with chronic polyneuropathy has recently been associated with evidence of active cytomegalovirus (CMV) infection by the polymerase chain reaction. We wished to test these findings and examined sera from patients with MAG-reactive or MAG-nonreactive paraproteinemic neuropathy and patients with paraproteinemia only for the presence of CMV DNA and anti-CMV antibodies. CMV DNA was not detected in sera from any patient group. Furthermore, anti-CMV antibody prevalence was normal and similar in all 3 groups. We therefore report no evidence of an association between CMV infection and anti-MAG/SGPG antibodies associated with paraproteinemic peripheral neuropathy.
Subject(s)
Cytomegalovirus/immunology , DNA, Viral/immunology , Demyelinating Diseases/immunology , Globosides/immunology , Immunoglobulin M/immunology , Myelin-Associated Glycoprotein/immunology , Aged , Enzyme-Linked Immunosorbent Assay , Female , Humans , Male , Middle Aged , Polymerase Chain ReactionABSTRACT
PURPOSE: Patients treated for Hodgkin disease (HD) are at increased risk for developing secondary neoplasms, including non-Hodgkin lymphoma (NHL). We present a patient who developed NHL (brain and lungs) as a second malignancy together with recurrent HD (bone marrow). Because HD and NHL have both been associated with Epstein-Barr virus (EBV), especially in the immunodeficient host, the tumor specimens were studied for the presence of EBV, and the possible role of immunodeficiency in the development of this second malignancy was assessed. METHODS AND RESULTS: Tumor specimens were analyzed by conventional histologic and immunohistochemical methods, EBV detection was determined by RNA in situ hybridization for EBV- encoded RNAs (EBERs). Histopathology showed diffuse large cell lymphoma of B-cell phenotype in specimens from lesions in the brain and lungs. These specimens were EBER+. HD specimens from all recurrences were evaluated and were EBER. CONCLUSIONS: This patient had received extensive chemoradiotherapy for recurrent HD, and presented with Pneumocystis pneumonia, a low absolute T-cell count, no response to mitogens in vitro, a second malignancy (EBV+NHL), and recurrent EBV-HD. We propose that the immunocompromised state of the patient played a significant role in the development of his second malignancy.
Subject(s)
Herpesvirus 4, Human , Hodgkin Disease/virology , Lymphoma, B-Cell/virology , Neoplasm Recurrence, Local/virology , Child , Herpesviridae Infections/complications , Herpesviridae Infections/virology , Hodgkin Disease/complications , Hodgkin Disease/pathology , Humans , Immunologic Deficiency Syndromes/complications , Immunologic Deficiency Syndromes/immunology , In Situ Hybridization , Lymphoma, B-Cell/complications , Lymphoma, B-Cell/pathology , Male , Neoplasm Recurrence, Local/pathology , Tumor Virus Infections/complications , Tumor Virus Infections/virologyABSTRACT
Chronic parvovirus B19 infection in the immunocompromised host may cause severe anaemia secondary to failure of erythropoiesis. This has been previously documented in patients with the Acquired Immune Deficiency Syndrome (AIDS), congenital immunodeficiencies and in children with acute lymphoblastic leukaemia during maintenance chemotherapy. We describe persistent parvovirus infection in a 14-year-old boy after HLA-matched sibling allogeneic bone marrow transplantation for acute lymphoblastic leukaemia in second remission.